Thanks to the large-scale development of our proven proprietary green biotechnology, compliant with the regulatory requirements of the European Union, the United States, and Canada, we will program a vast biomass to produce up to 90% of all plant-based ingredients used in the rapidly growing international industries of cosmetics, food additives, and nutritional health products.

We are ready to produce, ready to grow, ready to transform the industry

We are targeting to complete our Series A capital investment round in Q3-2026 to support the construction and operation of a pilot manufacturing facility (Aplantex Innovation Center) as well as the design and layout of our first large-scale commercial production plant. This is the natural evolution of the pilot R&D agreements signed in 2024 and 2025 with several strategic clients, including Symrise, a leader in the cosmetics and food industry based in Germany with an international presence. Through the strategic information obtained so far following the conclusion of 12 commercial collaboration agreements, Aplantex is finalizing its production planning for the next two years.

To harness any headwind, realize this plan, and pave the path to commercialization, we seek to raise Series A investment of CAD $20M, mainly equity leveraged with non-dilutive capital. To that effect, we are in active talks with Canadian, American, and European institutional investment groups. We look forward to maintaining our strong pace of growth.

Share : Back to blog